Message from Takahiro Ochiya, CSO

Why is the pathology of “cancer” complex?
This is because the "face” of cancer cells is complex and diverse and differs from individual to individual.

A multi-faceted approach is essential in order to understand these characteristics of cancer cells, and technological innovation and imaginative research ideas are required on a daily basis. The purpose of the Research Department of Theoria Science is to establish new methods of diagnosis and treatment for various diseases including cancer. We have specialized technologies in the areas of nucleic acid medicine, biological imaging, stem cells, regenerative medicine, cell engineering, and molecular oncology.

Takahiro Ochiya, CSO
And with our accumulated experience in these areas, we are constantly taking on the challenge of exploring new areas. Our accumulated know-how functions as a communication tool between cells, just like exosomes, extracellular vesicles that have grown into one of the areas of greatest global interest over the past ten years. In particular, we believe that the elucidation of the mechanism of cancer metastasis by exosomes and application to diagnosis as well as the development of new therapeutics targeting exosomes will be new future research areas. The role of exosomes in the progression not only of cancer but also of various diseases has already been elucidated. By undertaking research and development of the diagnostic methods and therapeutics targeting exosomes for all of these diseases, we will take on the challenge of relieving the suffering of the many who suffer from illness and realizing a "me-byo" society free of disease.

Management

Takayuki Mizutani

Takayuki MizutaniRepresentative Director

1997
Graduated from the Department of Chemistry and Biochemistry, Ohio State University, USA
2000
M.S. in Biochemistry, California State University Long Beach, USA
2000
Joined B-Bridge International, Inc. (San Jose, CA)
2003
Founded AVOCEL Inc. (Mt, View, CA)
2010
Founded IZM Corporation, Representative Director
2012
Completed doctoral program, Department of Molecular Pathology, Graduate School of Medicine, Tokyo Medical University (Ph.D.)
2012
Director, Bonac Corporation
2014
Representative Director, Theoria Science K.K.
Takahiro Ochiya

Takahiro OchiyaDirector, CSO

1988
Completed doctoral program, Graduate School of Medicine, Osaka University (Ph.D.)
1988
Instructor Assistant, Osaka University Institute for Molecular & Cellular Biology
1991
Postdoctoral Fellow, La Jolla Cancer Research Foundation (now the Sanford Burnham Prebys Medical Discovery Institute)
1993
Senior researcher, National Cancer Center Research Institute, later Head, Department of Molecular Oncology, and Head, Department of Cancer Metastasis Research
2010
Chief, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute
2012
Director, Theoria Science K.K.
2018
Professor, Institute of Medical Science, Tokyo Medical University
Akihiko Asami

Akihiko AsamiExternal Director

1985
Graduated from the Faculty of Economics, School of Political Science and Economics, Waseda University
1985
Joined The Fuji Bank, Limited
1996
Completed master’s program, Sloan School of Management, Massachusetts Institute of Technology, U.S.A.
1996
Joined Goldman Sachs Japan Investment Banking Division
2004
Managing Director, Goldman Sachs Japan Investment Banking Division
2009
Head, Technology, Media, and Telecom Sector Group and Head, Healthcare Group, Investment Banking Division, Deutsche Securities Inc.
2012
Head of Corporate Finance, Investment Banking Japan, Barclays Capital Japan Limited
2014
Division Head, Investment Banking Japan, Barclays Capital Japan Limited
2016
Vice President, Barclays Capital Japan Limited
2019
Director and CFO, Theoria Science K.K.
Yutaro Kasai

Yutaro KasaiPart-Time Auditor

2005
Graduated from the Graduate School of Agricultural and Life Sciences, The University of Tokyo
2005
Joined Goldman Sachs Japan Investment Banking Division
2006
Joined Bain Capital, LP
2009
Entered the Booth School of Business, University of Chicago
2011
Joined Unison Capital, Inc.
2015
Established Angel Bridge K.K., Representative Director
2019
Part-Time Auditor, Theoria Science K.K.

Company Overview

Mission

  • Prevention

    Preventive drug development

  • Early detection

    Early diagnostic drug development

  • Early treatment

    Early therapeutic drug development

  • Making current impossibilities future possibilities

    Taking on the challenge of development of therapeutic and diagnostic drugs for intractable diseases